MEDVi is a telehealth brand selling compounded programs, including QUAD for ED and GLP-1 weight-loss offers. Reputation questions usually arrive as “scam or real” searches after ads.
What Complaints Show Up Around MEDVi?
Typical telehealth complaint themes in this category are subscription billing, delayed shipments, declined prescriptions, and “not as advertised” compounding disclosures. We are not scraping or fabricating a complaint score. Check BBB-type listings, state boards, and the FDA letter as separate evidence types.
Should Flashy Doctor Ads Change My Decision?
2026 coverage has called out staged clinician photos and hard-sell health claims across telehealth advertising, and MEDVi has shown up in that broader conversation. A polished ad is not a license. Prefer a named researcher byline, primary documents, and your own clinician over a stock white-coat pitch.
Community anecdotes: Reddit roundup. Main file: review.
Sources Checked for This Page
- FDA warning letter MEDVi, LLC dba MEDVi, 721455, 20 February 2026.
- FDA product labels for sildenafil, tadalafil, and bremelanotide (Vyleesi).
- Brand-facing MEDVi pages and 2026 secondary reporting on the QUAD formula and list prices.
Individual ingredients such as sildenafil and tadalafil are FDA-approved for other indications; the combined compounded formulation has not been evaluated by the FDA as a finished product, standard for all compounded medicines.